<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029570</url>
  </required_header>
  <id_info>
    <org_study_id>PACE-FIB</org_study_id>
    <nct_id>NCT05029570</nct_id>
  </id_info>
  <brief_title>Heart Rate Regularization in Atrial Fibrilation and Heart Failure</brief_title>
  <acronym>PACE-FIB</acronym>
  <official_title>Conduction System PACing and Atrioventricular Node Ablation in Patients With hEart Failure, Left Ventricular Ejection Fraction &gt;40% and Permanent Atrial FIBrilation: the PACE-FIB Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel Rodríguez Muñoz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sociedad Castellana de Cardiologia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario 12 de Octubre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PACE-FIB trial is a multicentre, randomised, open-label clinical trial. Patients older&#xD;
      than 18 years, with permanent AF, LVEF&gt;40%, average resting heart rate ≤ 110 beats per minute&#xD;
      (bpm), at least one hospitalisation due to HF in the previous year and basal NT-proBNP&#xD;
      level&gt;900 pg/ml will be randomised to either CSP and subsequent AV node ablation&#xD;
      (intervention group) vs. pharmacologic rate control optimised according to clinical practice&#xD;
      guidelines. The impact of both strategies on a composite primary endpoint of all-cause&#xD;
      mortality, HF hospitalisation and worsening HF will be evaluated during a 36-month follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Permanent atrial fibrillation (AF) causes beat-to-beat heart rate irregularity, which has&#xD;
      shown to decrease cardiac output. Observational data suggest that heart rate regularization&#xD;
      through atrioventricular (AV) node ablation and pacemaker implantation improves outcomes in&#xD;
      heart failure (HF) patients. However, no trials have been conducted to assess its potential&#xD;
      benefit in HF and left ventricular ejection fraction (LVEF)&gt;40%, a population in whom&#xD;
      treatment strategies effectively improving outcomes are scarce.&#xD;
&#xD;
      The goal of this trial is to assess the benefit of heart rate regularization through AV node&#xD;
      ablation and conduction system pacing (CSP) in patients with permanent AF and HF with&#xD;
      preserved or mildly reduced systolic function. The investigators hypothesize that heart rate&#xD;
      regularization added to physiological pacing - preventing the deleterious effect of right&#xD;
      apical pacing - reduces mortality, HF hospitalisations or worsening HF in these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Medical Device: Conduction System Pacing (pacemaker implantation)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Clinical outcomes will be adjudicated by the investigator and reviewed by the Clinical Events Committee, that will be blind to treatment received by the patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Composite primary endpoint</measure>
    <time_frame>36 months</time_frame>
    <description>All-cause mortality, heart failure hospitalisation and worsening heart failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>36 months</time_frame>
    <description>Mortality due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>36 months</time_frame>
    <description>Mortality due to cardiovascular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure hospitalization</measure>
    <time_frame>36 months</time_frame>
    <description>Hospitalization due to heart failure decompensation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening heart failure</measure>
    <time_frame>36 months</time_frame>
    <description>An episode of heart failure diagnosed based on symptoms, signs, imaging and analytical criteria that requires unplanned medical attention and intravenous diuretic therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned cardiovascular hospitalisation</measure>
    <time_frame>36 months</time_frame>
    <description>Unplanned cardiovascular hospitalisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>12 months</time_frame>
    <description>assessed by the Simpson method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular dimension</measure>
    <time_frame>12 months</time_frame>
    <description>end-diastolic and end-systolic volumes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in degree of mitral regurgitation</measure>
    <time_frame>12 months</time_frame>
    <description>Change in degree of mitral regurgitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional status</measure>
    <time_frame>36 months</time_frame>
    <description>Assessed by New York Heart Association (NYHA) on a I to IV scale (I being better functional status and IV worst possible functional status)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse events during or in the first 30-days following pacemaker implantation</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of patients suffering one of the following: death, cardiac tamponade, perforation requiring cardiac surgery, pneumothorax, haemothorax, device infection, endocarditis, lead displacement requiring re-intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse events during or in the first 30-days following atrioventricular node ablation</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of patients suffering one of the following: death, cardiac tamponade, perforation requiring cardiac surgery, puncture site vascular complications requiring vascular surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">334</enrollment>
  <condition>Heart Failure</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Conduction System Pacing and AV node ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atrioventricular node ablation and subsequent conduction system pacing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical treatment for rate control of AF</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Pharmacological rate control based on clinical practice guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conduction System Pacing (pacemaker implantation)</intervention_name>
    <description>Conduction System Pacing (pacemaker implantation) and Atrioventricular node ablation</description>
    <arm_group_label>Conduction System Pacing and AV node ablation</arm_group_label>
    <other_name>Atrioventricular node ablation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Permanent atrial fibrillation&#xD;
&#xD;
          -  At least one episode of hospitalisation due to heart failure in the previous 12&#xD;
             months.&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt; 40%&#xD;
&#xD;
          -  Average resting heart rate ≤ 110 beats per minute&#xD;
&#xD;
          -  NT-proBNP ≥ 900 pg/ml in the 30 days prior to enrollment&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Capacity to understand the nature of the study, legal ability and willingness to give&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe frailty (Clinical Frailty Scale ≥ 7) or comorbidity reducing life expectancy to&#xD;
             &lt; 12 months.&#xD;
&#xD;
          -  Acute heart failure at the time of enrollment or systolic blood pressure &lt; 80 mmHg in&#xD;
             the absence of inotropic agents.&#xD;
&#xD;
          -  Severe chronic kidney disease (estimated Glomerular Filtration Rate ≤ 20 ml/1,73 m2&#xD;
&#xD;
          -  Severe mitral or aortic valvular heart disease&#xD;
&#xD;
          -  Anaemia (Haemoglobin &lt; 10 g/dl)&#xD;
&#xD;
          -  Morbid obesity (BMI ≥ 35)&#xD;
&#xD;
          -  Severe Chronic Obstructive Pulmonary Disease (Gold ≥ 3)&#xD;
&#xD;
          -  Presence of a different indication for pacing of implantable&#xD;
             cardioverter-defibrillator (ICD)&#xD;
&#xD;
          -  Obstructive hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Infiltrative cardiomyopathy (amyloidosis, sarcoidosis, Fabry disease, others)&#xD;
&#xD;
          -  Simultaneous participation in a different trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Arribas Ynsaurriaga, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Rodriguez Muñoz, MD, PhD</last_name>
    <phone>+34 917792742</phone>
    <email>danielantonio.rodriguez@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Isabel Castillo Varón, PhD</last_name>
    <phone>+34 917792742</phone>
    <email>aicastillo.imas12@h12o.es</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario 12 de Octubre</investigator_affiliation>
    <investigator_full_name>Daniel Rodríguez Muñoz</investigator_full_name>
    <investigator_title>Consultant in Cardiac Electrophysiology, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation;</keyword>
  <keyword>heart failure;</keyword>
  <keyword>conduction system pacing;</keyword>
  <keyword>heart rate regularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

